200 related articles for article (PubMed ID: 31256051)
1. Direct oral anticoagulant and AKI: apixaban-induced acute interstitial nephritis.
DiMaria C; Hanna W; Murone J; Reichart J
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31256051
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulant and kidney injury: apixaban-related acute interstitial nephritis.
Abdulhadi B; Mulki R; Goyal A; Rangaswami J
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28847995
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban-Induced Acute Interstitial Nephritis: A Case Report.
Zafar F; Iqbal AM; Mubarik A; Rojas M; Muddassir S
Am J Case Rep; 2019 Nov; 20():1719-1722. PubMed ID: 31748498
[TBL] [Abstract][Full Text] [Related]
4. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
Adachi T; Hoshino H; Takagi M; Fujioka S;
Cerebrovasc Dis Extra; 2017; 7(1):62-71. PubMed ID: 28376486
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
[TBL] [Abstract][Full Text] [Related]
6. Azithromycin-Induced, Biopsy-Proven Acute Interstitial Nephritis in an Adult Successfully Treated with Low-Dose Corticosteroids.
Woodruff AE; Meaney CJ; Hansen EA; Prescott GM
Pharmacotherapy; 2015 Nov; 35(11):e169-74. PubMed ID: 26598102
[TBL] [Abstract][Full Text] [Related]
7. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
Steed MB; Swanson MT
Oral Maxillofac Surg Clin North Am; 2016 Nov; 28(4):515-521. PubMed ID: 27624772
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
[TBL] [Abstract][Full Text] [Related]
9. Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury.
Towers W; Nguyen SN; Ruegger MC; Salazar E; Donahue KR
Ann Pharmacother; 2022 Jun; 56(6):656-663. PubMed ID: 34541895
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulant drugs (DOAC).
Blum RA; Lindfield D
J Cataract Refract Surg; 2016 Jan; 42(1):171-2. PubMed ID: 26948793
[No Abstract] [Full Text] [Related]
12. Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation.
Vu TT; Gooderham M
J Cutan Med Surg; 2017; 21(6):540-550. PubMed ID: 28639463
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
[TBL] [Abstract][Full Text] [Related]
15. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
[TBL] [Abstract][Full Text] [Related]
16. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).
Perlman A; Wanounou M; Goldstein R; Choshen Cohen L; Singer DE; Muszkat M
CNS Drugs; 2019 Dec; 33(12):1223-1228. PubMed ID: 31686406
[TBL] [Abstract][Full Text] [Related]
17. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
20. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
